



INTERCEPT PHARMACEUTICALS Intercept INC. Rank 231 of 371







The relative strengths and weaknesses of INTERCEPT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTERCEPT PHARMACEUTICALS INC. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 55% points. The greatest weakness of INTERCEPT PHARMACEUTICALS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is -248%, being 84% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	482,425
Cost of Goods Sold	2,519
Intangible Assets	0
Liabilities, Current	114,205
Liabilities, Non-Current	375,021
Other Assets	16,331
Other Compr. Net Income	-1,473
Other Expenses	0
Other Liabilities	811
Other Net Income	-23,752
Property and Equipment	10,411
Research and Development	207,301
Revenues	179,804
Selling, General and Administrative Expense	255,474

Output Variable	Value in 1000 USD
Assets	509,167
Liabilities	490,037
Expenses	465,294
Stockholders Equity	19,130
Net Income	-309,242
Comprehensive Net Income	-309,978
Economic Capital Ratio	-248%

